Dr. Eric J. Boren, MD
Allergy & Immunology (Allergy & Immunology Physician)
2121 17th St
Bakersfield, CA 93301
Who else practices at this address →
Kern County includes primary care (47% of residents) and dental (8% of residents) and mental health (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Davis School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 375
Licensed in California since 2001, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of California, Davis School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
CA license A77407 (first issued 2001; current) -
Internal Medicine Physician
CA license A774070
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bakersfield Memorial Hospital Bakersfield, CA
- Sierra View Medical Center Porterville, CA
Medical groups
- Kern Allergy Medical Clinic Inc (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 375
- Services billed
- 17,006
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Professional service for preparation and provision of 1 or more antigens | 5,590 | 114 |
| Test for allergy using allergenic extract | 5,571 | 68 |
| Professional service for multiple injections of allergen | 2,285 | 131 |
| Test for allergy using allergenic extract injected into skin | 1,137 | 54 |
| Test for allergy using skin patch | 576 | 16 |
| Professional service for preparation and provision of single-dose vial of allergen | 510 | 11 |
| Established patient office or other outpatient visit, 20-29 minutes | 405 | 243 |
| Established patient office or other outpatient visit, 30-39 minutes | 207 | 133 |
| Professional service for single injection of allergen | 164 | 20 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 88 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Bakersfield, CA | 145 |
| Azelastine Hcl Other prescribers in Bakersfield, CA | 130 |
| Levocetirizine Dihydrochloride Other prescribers in Bakersfield, CA | 125 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Bakersfield, CA | 107 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Bakersfield, CA | 98 |
| Fluticasone Propionate Other prescribers in Bakersfield, CA | 91 |
| Famotidine Other prescribers in Bakersfield, CA | 57 |
| Ipratropium Bromide Other prescribers in Bakersfield, CA | 47 |
| Hydroxyzine Hcl Other prescribers in Bakersfield, CA | 33 |
| Triamcinolone Acetonide Other prescribers in Bakersfield, CA | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 93 payments worth $2,245 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $393 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $352 |
| Amgen Inc. | $259 |
| Novartis Pharmaceuticals Corporation | $186 |
| Ionis Pharmaceuticals, Inc. | $153 |
| Csl Behring | $138 |
| Pharming Healthcare, Inc. | $111 |
| Ars Pharmaceuticals Operations, Inc. | $80.03 |
| Food and Beverage | $2,059 |
|---|---|
| Education | $162 |
| Consulting Fee | $23.72 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Mar 25, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $99.26 |
| Sanofi-aventis U.S. LLC Sep 2, 2025 | Education DUPIXENT · Immunology · in-kind | $55.99 |
| Adma Biomanufacturing LLC May 22, 2025 | Consulting Fee | $23.72 |
| Regeneron Healthcare Solutions, Inc. Mar 10, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $6.77 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 7 companies. The companies reported $793,158 in research payments for these studies, mostly to the institutions running them.
- A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontan…
Novartis Pharmaceuticals Corporation - A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urtic…
Novartis Pharmaceuticals Corporation - Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06572228 - A phase one,open label,single dose study to evaluate the pharmacokinetics of inhaled in adolescents with asthma
AstraZeneca Pharmaceuticals LP - Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Genzyme Corporation · Active, not recruiting · NCT05097287 - A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic O…
AstraZeneca Pharmaceuticals LP - A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma
Incyte Corporation - A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (…
Novartis Pharmaceuticals Corporation - A phase 2B randomized doubleblind 12WEEK placebocontrolled study with a 12WEEK doubleblind extension period to evaluate the efficacy safety and tolerability of ritlecitinib PF06651600 in adult participants with ch…
Pfizer Inc. - A phase 3, 24-week, randomized, double-blind, parallel-group bayesian
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.